Michael Makris/LinkedIn
Jan 19, 2026, 14:17
Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Another study showing the benefit of low-dose emicizumab (Hemlibra) in hemophilia A.
The patients were receiving half the approved dose of the drug.
Despite this, the mean Annual Bleed Rate (ABR) was 0.4, the median was 0.0 and 67% had zero bleeds.
If you saw these data, you would not know that the patients were only using half the approved dose.
Is it not time for a randomised study in Europe or North America of full vs half-dose emicizumab in severe hemophilia A?
Roche will clearly never do such a study, it will need to be done independently.”
Stay updated with Hemostasis Today.
-
Mar 10, 2026, 12:23Bastu Odoka: The Laboratory’s Role in Preventing RhD Disease
-
Mar 10, 2026, 12:22Kalyan Roy: Rediscovering Cold-Stored Platelets in Modern Transfusion Medicine
-
Mar 10, 2026, 04:15Abdul Mannan: NK Cell ALL and the Diagnostic Challenge of a Provisional Entity:
-
Mar 9, 2026, 16:51Melanie Daniel: Exploring Bleeding Complications in Patients with LVADs
-
Mar 9, 2026, 16:30Mohamed Sikkander Abdul Razak: Recent Breakthroughs in Stem Cell Therapy for Diabetes Treatment
-
Mar 9, 2026, 16:28Augustina Isioma Ikusemoro: Is Blood Really Affordable?
-
Mar 9, 2026, 16:26Todd Maderis: Great Conversation on Effective Treatment of Chronic Infections
-
Mar 9, 2026, 16:25Denise Braendgaard: How Partnership is Turning Ambition Into Action
-
Mar 9, 2026, 16:10Veronica Sanchez: Recognizing the Risks of Preeclampsia During Pregnancy and Newly Postpartum